2
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36982 |
CXCR3 Antagonist 6c
|
||
CXCR3 antagonist 6c is an antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3).1It inhibits calcium mobilization induced by chemokine (C-X-C motif) ligand 11 (CXCL11) in HEK293 cells expressing the human receptor (IC50= 0.06 μM). It is selective for CXCR3 over a panel of 14 human G protein-coupled receptors at 10 μM. CXCR3 antagonist 6c inhibits CXCR3-mediated migration of isolated human T cells (IC50= ~100 nM). 1.Cole, A.G., Stroke, I.L., Brescia, M.-R., et al.Identification and initial eva... | |||
T83763 |
EPI-X4 TFA
Endogenous Peptide Inhibitor of CXCR4 |
||
EPI-X4是一种源于人血清白蛋白408-423氨基酸的内源性肽段,是趋化因子(C-X-C基序)受体4 (CXCR4)的拮抗剂。在0.8至1,000µM的浓度范围内,EPI-X4能抑制表达CXCR4的HEK293细胞中由趋化因子(C-X-C基序)配体12 (CXCL12)诱发的钙离子动员和受体内化。EPI-X4还能抑制CXCL12诱导的Jurkat T细胞和人类CD34+造血干细胞的迁移。体内实验中,EPI-X4(16µmol/kg)在急性过敏性气道高嗜酸性粒细胞疾病的小鼠模型中减少了Cxcr4依赖的炎症细胞气道浸润。慢性肾脏病患者尿液中EPI-X4的水平增高,并与肾小球滤过率(GFR)成反比。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-05337 |
CXCL16 Protein, Human, Recombinant (His)
chemokine (C-X-C... |
Human | HEK293 Cells |
CXCL16 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 20.5 kDa and the accession number is Q9H2A7. | |||
TMPY-02754 |
CXCL16 Protein, Rat, Recombinant (His)
chemokine (C-X-C... |
Rat | HEK293 Cells |
CXCL16 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 20.4 kDa and the accession number is Q6AXU5. | |||
TMPY-03896 |
CXCL16 Protein, Canine, Recombinant (hFc)
chemokine (C-X-C... |
Canine | HEK293 Cells |
CXCL16 Protein, Canine, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 47.1 kDa and the accession number is XP_849304.2. | |||
TMPY-03025 |
CXCL16 Protein, Rat, Recombinant (hFc)
chemokine (C-X-C... |
Rat | HEK293 Cells |
CXCL16 Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46 kDa and the accession number is A0A6M4C4P9. | |||
TMPY-03771 |
CXCL16 Protein, Canine, Recombinant (His)
chemokine (C-X-C... |
Canine | HEK293 Cells |
CXCL16 Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 21.5 kDa and the accession number is XP_849304.2. | |||
TMPY-01269 |
CXCL16 Protein, Mouse, Recombinant (His)
CXCL16v2,b2b498... |
Mouse | HEK293 Cells |
CXCL16 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 20.5 kDa and the accession number is A2CFE9. | |||
TMPY-00641 |
LEC/CCL16 Protein, Human, Recombinant (His)
SCYL4,HCC |
Human | E. coli |
CCL16, a chemokine poorly characterized at the functional level. Human CCL16 is a member of the CC family, and its gene maps to human chromosome 17q. In the mouse, only a pseudogene has been identified to date. CCL16 is a functional ligand for CCR1, CCR2, CCR5, and CCR8. Recombinant CCL16 demonstrated chemotactic activity on human monocytes and lymphocytes. Based on the ability of human chemokines to exert activity on and bind to murine receptors, the TSA mouse adenocarcinoma cell line was trans... | |||
TMPJ-00018 |
CCL16 Protein, Human, Recombinant
NCC-4,Lymphoc |
Human | E. coli |
CCL16 is a member of CC chemokine family. CCL16 cDNA encodes a 120 amino acid peptide along with a 23 amino acids signal peptide that is cleaved to generate 97 amino acid protein. CCL16 is distantly related to other CC chemokines, showing less than 30% sequence identity. CCL16 elicits its effects on cells by interacting with cell surface chemokine receptors such as CCR1, CCR2, CCR5 and CCR8. Recombinant CCL16 has been shown to chemoattract human monocytes and THP1 cells but not resting lymphocyt... | |||
TMPY-02563 |
VSTM1 Protein, Human, Recombinant (hFc)
VSTM1,V-set and transmembrane domain conta... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... | |||
TMPY-02555 |
VSTM1 Protein, Human, Recombinant (His)
SIRL-1,UNQ3033,MGC119161,V-set an... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,C... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |